A small piece of the multibillion-dollar restructuring at Pfizer has a light at the end of the tunnel, and it’s in Boulder, CO.
Just a few months after research operations ended at the home of Array BioPharma, the small molecule drugmaker that Pfizer bought for $11.4 billion in 2019, some former employees already have a new home: Ambrosia Biosciences.
The Colorado biotech emerged on Tuesday with the initial close of a $16 million Series A to discover and test new oral small molecules for obesity. It has about 15 former Array employees and plans to move into a lab in the fourth quarter, president and founder Nick Traggis told Endpoints News.
Kyle Lefkoff Boulder Ventures and BVF Partners led the Series A, which could grow to about $25 million, according to an SEC filing from this week. Boulder…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
